GlassScriptPhysician profile
Janet A Davis
NPI 1124019302
$2,352.96
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $279 · 2021: $615 · 2022: $451 · 2023: $477 · 2024: $32.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $406.63 | 2019-2023 | Liletta, Lo Loestrin Fe, Orilissa |
| Evofem Biosciences, INC. | $173.37 | 2020-2023 | Phexxi |
| Bayer Healthcare Pharmaceuticals INC. | $168.68 | 2019-2023 | |
| Baxter Healthcare | $162.79 | 2020-2021 | |
| Exeltis, USA INC. | $123.93 | 2019-2023 | Slynd |
| Mayne Pharma Commercial LLC | $99.76 | 2021-2023 | |
| Pfizer INC. | $94.52 | 2019-2023 | |
| Therapeuticsmd, INC. | $89.77 | 2019-2022 | |
| Coopersurgical, INC. | $81.23 | 2019-2020 | |
| Hologic Sales and Service, LLC | $77.55 | 2019-2023 | Acessa Provu System, Aptima |
| Daiichi Sankyo INC. | $76.81 | 2020-2021 | |
| Agile Therapeutics, INC. | $75.83 | 2021-2023 | Twirla |
| Aspira Women'S Health INC | $67.68 | 2021 | |
| Sumitomo Pharma America, INC. | $67.16 | 2023 | Myfembree |
| Myovant Sciences INC. | $65.99 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $54.38 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $53.76 | 2019-2022 | |
| Duchesnay USA Incorporated | $49.32 | 2019 | |
| Exact Sciences Corporation | $44.91 | 2023 | Cologuard Collection Kit |
| Organon LLC | $43.58 | 2022-2023 | Nuvaring, Nexplanon |
| Shield Therapeutics INC | $36.30 | 2023 | Accrufer |
| Astellas Pharma US INC | $29.72 | 2023-2024 | Veozah, Myrbetriq |
| Avion Pharmaceuticals | $29.08 | 2021 | |
| Minerva Surgical, INC | $28.67 | 2019-2024 | |
| Siemens Medical Solutions USA, INC. | $28.05 | 2022 | |
| Amgen INC. | $27.26 | 2019 | |
| Merck Sharp & Dohme LLC | $24.86 | 2019-2021 | |
| Allergan, INC. | $23.88 | 2020 | |
| Monaghan Medical Corporation | $19.55 | 2023 | Aeroeclipse |
| Millicent US INC | $14.22 | 2023 | Intrarosa |
| Currax Pharmaceuticals LLC | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.